This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Metabolix's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Metabolix, Inc. (MBLX)

Q2 2012 Earnings Call

July 26, 2012 04:30 p.m. ET

Executives

Rick Eno, President & CEO

Joe Hill – CFO

Analysts

Laurence Alexander – Jefferies

Mike Ritzenthaler -- Piper Jaffray

JinMing Liu -- Ardour Capital

Jeff Osborne -- Stifel Nicolaus

Uu Yang – JPMorgan

Presentation

Operator

Good afternoon, ladies and gentlemen, thank you for standing by. Welcome to the Metabolix Incorporated Second Quarter 2012 Earnings Conference Call. Today s call is being recorded. At this time, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. Instructions will be provided at that time for you to queue up for your questions.

I would like to turn the conference over to Ms. Allison Townsend of ICR. Please go ahead ma am.

Allison Townsend

Thank you, and good afternoon, everyone. After the market closed today, Metabolix issued two press releases, the second quarter 2012 financial results press release and the announcement of a letter of intent with Antibióticos to manufacture Mirel Biopolymers. If you have not received a copy of these press releases copies may be found on the website at www.metabolix.com in the Investor Relations section.

In addition, today we have provided several slides to accompany the presentation. These slides are available via webcast on the Metabolix website in conjunction with today s call.

Making the presentation today will be Richard Eno, President and Chief Executive Officer of Metabolix; and Joseph Hill, Chief Financial Officer of the company. They are joined by Oliver Peoples, a co-founder of Metabolix and Chief Scientific Officer.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,596.35 -350.33 -1.95%
S&P 500 2,057.64 -43.85 -2.09%
NASDAQ 4,958.4680 -122.0370 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs